License

FDCTech's Quarterly Release for the Second Quarter (FY23 Q2) Results

Retrieved on: 
Monday, August 14, 2023
ETF, Education, ADS, Malta Financial Services Authority, Law, Companies Act, OTC, Contract for difference, Growth, License, The Company, AD, Hand, MFSA, Investment Company Act of 1940, Rare-earth element, Cryptocurrency, Financial adviser

Irvine, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- FDCTech, Inc. ("FDC" or the "Company," OTCQB: FDCT), a fintech-driven company specializing in buying and integrating small to mid-size legacy financial services companies, today announced the following results for the three and six months ending June 30, 2023, as compared to the corresponding period of June 30, 2022:

Key Points: 
  • The Company reported a net income of $922,343 and $685,168 for the three and six months ending June 30, 2023.
  • The gross margin generated for the three months ending June 30, 2023, and 2022 were $442,657 and $155,121, an increase of 185% from the previous period.
  • The cash on hand was $127,057 as of June 30, 2023, compared to $264,829 on December 31, 2022.
  • Please visit our SEC filings or Company's website for more information on the full results and management's plan.

Verasonics Launches Enhancements for the Vantage™ Research Ultrasound System: Permissive License Sharing and New Transducers

Retrieved on: 
Tuesday, August 15, 2023
Research, Technology, Medical Devices, Health Technology, Audio, Video, Biotechnology, Hardware, Radiology, Health, Science, RCA, Hertz, Transducer, UTA, High frequency, License, Software, Medical imaging, Management, Vantage, Canon

Verasonics, Inc. , the leader in research ultrasound, today announced it has enhanced the Vantage Research Ultrasound System with the introduction of the Verasonics Permissive License and new transducers, including a 15 MHz Row-Column Array and three general imaging transducers.

Key Points: 
  • Verasonics, Inc. , the leader in research ultrasound, today announced it has enhanced the Vantage Research Ultrasound System with the introduction of the Verasonics Permissive License and new transducers, including a 15 MHz Row-Column Array and three general imaging transducers.
  • “Today, we are excited to offer the Verasonics Permissive License which was based on customer feedback,” said Jon K. Daigle, President and Chief Executive Officer at Verasonics.
  • Verasonics provides example scripts for imaging and simulation support for the transducer with the Vantage 256 Research Ultrasound System.
  • Verasonics has launched a new series of general imaging transducers in collaboration with HUMANSCAN to provide more options for research imaging needs.

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

Retrieved on: 
Thursday, June 29, 2023
Volunteering, Infection, Single, Safety, Medical college, Satyam Infoway Ltd. v. Sifynet Solutions Pvt. Ltd., Government Medical College and Hospital, Sundargarh, API, COVID-19, End-user license agreement, NYSE, Clinical trial, Licensee, Patient, Evaluation, Coronavirus, Observation, Clinical, License, Hospital, Protocol, Birth control, Pharmaceutical industry, COVID

The Company is a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, called "nanoviricides".

Key Points: 
  • The Company is a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, called "nanoviricides".
  • Ltd., Aurangabad, Maharashtra, India, to develop and prosecute the clinical trials applications and conduct the clinical trials.
  • The Phase 1a/1b clinical trial labeled KM-NVCoV2-001 is being conducted at a single site, Clinical Research Unit in the Department of Clinical Pharmacology, Mahatma Gandhi Mission's Medical College and Hospital, Aurangabad, India.
  • The clinical trial protocol and information can be found in India's official clinical trials registry, https://ctri.nic.in/Clinicaltrials/pubview.php by entering the sponsor's name "Karveer Meditech" and selecting the search criterion "Sponsor."

Lightwave Logic Provides Second Quarter 2023 Corporate Update

Retrieved on: 
Thursday, August 10, 2023
Cloud, Patent, Intellectual property, Modulation, Technology transfer, Telecommunications, Internet, Serbisyo All Access, Communes of Burundi, End-user license agreement, International conference on Physics of Light–Matter Coupling in Nanostructures, Polymer, EPIC, LightWave 3D, IP, Ladenburg, Sale, Ladenburg Thalmann, Logic, Publication, European Conference on Computational Biology, License, Artificial intelligence, Silicon, PIC, Programmable interrupt controller, EO, Conference, Licensed production, Cryptocurrency, 3D printing, Management, Microscope, Video game

ENGLEWOOD, Colo., Aug. 10, 2023 /PRNewswire/ -- Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic (EO) polymers to transmit data at higher speeds with less power in a small form factor, today provided a corporate update in conjunction with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2023.

Key Points: 
  • ENGLEWOOD, Colo., Aug. 10, 2023 /PRNewswire/ -- Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic (EO) polymers to transmit data at higher speeds with less power in a small form factor, today provided a corporate update in conjunction with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2023.
  • Second Quarter 2023 and Subsequent Company Highlights:
    Began commercialization of electro-optic polymer materials with first commercial material supply license agreement for Perkinamine® chromophore materials.
  • "The second quarter of 2023 was by underscored by our first commercial agreement – a milestone achievement for Lightwave Logic that we are incredibly proud of," said Dr. Michael Lebby, Chairman and Chief Executive Officer of Lightwave Logic.
  • "We continued to solidify our IP moat in the second quarter with three new patent issuances and publications.

RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company

Retrieved on: 
Wednesday, August 9, 2023
Transfer, Radium, Communication, Second Amendment to the United States Constitution, Australian Company Number, University, Senior, Ingenu, Letter of intent, Intellectual property, Service, CSO, Research, License, Securities and Exchange Commission (Philippines), LOI, Sale, End-user license agreement, Patent, Hale v. Committee on Character and Fitness for the State of Illinois, University of Illinois Urbana-Champaign, Trustee, OTC, Security (finance), MISA, Letter, Obstructive sleep apnea, RespireRx, Pharmaceutical industry

The Exclusive License permits the sublicensor to grant written sublicenses of its rights under the Exclusive License.

Key Points: 
  • The Exclusive License permits the sublicensor to grant written sublicenses of its rights under the Exclusive License.
  • The Sublicense is essentially a direct pass-through of all of the rights and obligations associated with the Exclusive License to ResolutionRx as sublicensee from RespireRx as sublicensor.
  • In consideration for the License and Sublicense, ResolutionRx issued 25,000,000 Ordinary Shares of ResolutionRx to RespireRx pursuant to a stock transfer agreement plus the payment of US$1 to RespireRx.
  • Our service agreements with RespireRx and iNGENu will provide the needed infrastructure for operations that have recently begun.

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Retrieved on: 
Monday, August 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Cognition, Seizure, Therapy, American Epilepsy Society, Health care, FALCON, CTA, Medicine, Dravet syndrome, Oles, Congress, Patient, ADOA, Acadia Pharmaceuticals, OPA1, ASO, Diagnosis, AES, License, Stoke, Collaboration, Safety, Behavior, MHRA, Disease, Pharmaceutical industry, Cryptocurrency

“We recently shared positive new data supporting the potential for STK-001 as the first disease-modifying treatment for Dravet syndrome.

Key Points: 
  • “We recently shared positive new data supporting the potential for STK-001 as the first disease-modifying treatment for Dravet syndrome.
  • Single and multiple doses of STK-001 from 10mg up to 70mg have been generally well tolerated.
  • During the quarter ended June 30, 2023, Stoke updated its estimate of the total effort it expected to expend to satisfy its performance obligations under the Acadia collaboration.
  • As a result, Stoke recorded a cumulative catch-up adjustment of $(5.3) million which resulted in a reversal of revenue during the quarter ended June 30, 2023.

NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain

Retrieved on: 
Monday, August 7, 2023
SAB, Patent, Rockefeller Neuroscience Institute, Nociception, Spinal cord, Perception, United States Air Force Scientific Advisory Board, NMDA, Research, Brain, CNS, Feinberg School of Medicine, Pain, US, Crave, Thalamus, Neuropathic pain, Ketamine, DCS, License, Northwestern University, Dark Enlightenment, Dietary supplement, Pharmaceutical industry, Vaccine, Anesthesia, Chronic pain, Surgery, Medicine, Northwestern

The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-101 to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids.

Key Points: 
  • The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-101 to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids.
  • "We delighted welcome Dr. Apkarian to the NRx SAB," said Jonathan Javitt, Chief Scientist and Founder of NRx Pharmaceuticals.
  • "Adding a scientist of Vania's caliber will be invaluable to advancing our clinical program in Chronic Pain."
  • In June 2023, the Company announced a focus on chronic pain as the next focus on NRX-101's development.

Asep Inc. Obtains Exclusive Worldwide License from the University of British Columbia for Ground-breaking Medical Device Coating Technology

Retrieved on: 
Wednesday, August 2, 2023
Agreement, Infection, Contact, Minority, ASEP, Catheter, CSE, University, MI, Diabetes, CVC Capital Partners, CVC, FSE, International finance, USD, Centers for Disease Control and Prevention, Titanium, CDC, End-user license agreement, Incidence, Good, PMA, Central venous catheter, Hospital, Prosthesis, Patient, National Healthcareer Association, Patent, Stent, Growth, Conditional sentence, License, FDA, UBC, Fungal infection, Glass, Multilateral, Acquisition, Safety, Pharmaceutical industry, Medical device, Security (finance), Research

Catheters are an excellent example of medical instruments that can cause serious infections.

Key Points: 
  • Catheters are an excellent example of medical instruments that can cause serious infections.
  • According to the Center for Disease Control and Prevention (CDC), approximately 90% of serious infections caused by catheters are associated with central venous catheters (CVCs).
  • UBC and the non-waiving inventors of the Technology will collectively own the remaining 12% of the issued and outstanding shares of SafeCoat in consideration for the exclusive license grant.
  • Dr. Robert E. W. Hancock, Founder and CEO of Asep Inc., is one of the four non-waiving inventors of the SafeCoat Technology.

Asep Inc. Obtains Exclusive Worldwide License from the University of British Columbia for Ground-breaking Medical Device Coating Technology

Retrieved on: 
Tuesday, August 1, 2023
Agreement, Infection, Contact, Minority, ASEP, Catheter, CSE, University, MI, Diabetes, CVC Capital Partners, CVC, FSE, International finance, USD, Centers for Disease Control and Prevention, Titanium, CDC, End-user license agreement, Incidence, Good, PMA, Central venous catheter, Hospital, Prosthesis, Patient, National Healthcareer Association, Patent, Stent, Growth, Conditional sentence, License, FDA, UBC, Fungal infection, Glass, Multilateral, Acquisition, Safety, Pharmaceutical industry, Medical device, Security (finance), Research

Catheters are an excellent example of medical instruments that can cause serious infections.

Key Points: 
  • Catheters are an excellent example of medical instruments that can cause serious infections.
  • According to the Center for Disease Control and Prevention (CDC), approximately 90% of serious infections caused by catheters are associated with central venous catheters (CVCs).
  • UBC and the non-waiving inventors of the Technology will collectively own the remaining 12% of the issued and outstanding shares of SafeCoat in consideration for the exclusive license grant.
  • Dr. Robert E. W. Hancock, Founder and CEO of Asep Inc., is one of the four non-waiving inventors of the SafeCoat Technology.

Travelzoo Reports Second Quarter 2023 Results

Retrieved on: 
Thursday, July 27, 2023
Operating cost, Advertising, Travel, Income tax, GAAP, Jack's Flight Club, Ratio, License, Acquisition, Nature, Growth, EPS, Second, Social media, Music, Bank, Tourism, Travelzoo

NEW YORK, July 27, 2023 /PRNewswire/ -- Travelzoo® (NASDAQ: TZOO):

Key Points: 
  • NEW YORK, July 27, 2023 /PRNewswire/ -- Travelzoo® (NASDAQ: TZOO):
    Travelzoo, a global Internet media company that provides exclusive offers and experiences for members, today announced financial results for the Second quarter ended June 30, 2023.
  • The reported net income attributable to Travelzoo from continuing operations was $2.6 million for Q2 2023.
  • In Europe, the unduplicated number of Travelzoo members was 9.2 million as of June 30, 2023, up 1% from June 30, 2022.
  • Travelzoo will host a conference call to discuss second quarter 2023 results today at 11:00 a.m.